Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) ...
A new breakthrough study from the Rotman Research Institute at Baycrest, University of Toronto (Motsenyat et al., Brain Stimulation 2025) shows that brief sessions of pulsed photobiomodulation (PBM) ...
Controlling light is an important technological challenge—not just at the large scale of optics in microscopes and telescopes ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Santa Barbara-based Lucidean, a deep-tech startup working at the cutting edge of optical interconnect technologies, has ...
Scientists have uncovered a way to manipulate the pathway in monkey brains that puts the brakes on motivation.
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback